Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) Director Nancy A. Simonian sold 37,070 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $0.27, for a total value of $10,008.90. Following the transaction, the director now directly owns 4,000 shares of the company's stock, valued at approximately $1,080. The trade was a 90.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Syros Pharmaceuticals Stock Down 1.2 %
NASDAQ SYRS opened at $0.25 on Thursday. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. Syros Pharmaceuticals, Inc. has a twelve month low of $0.18 and a twelve month high of $8.17. The stock has a fifty day simple moving average of $1.58 and a 200-day simple moving average of $3.29.
Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the firm posted ($1.35) earnings per share. On average, sell-side analysts expect that Syros Pharmaceuticals, Inc. will post -2.94 earnings per share for the current year.
Institutional Inflows and Outflows
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Several institutional investors have recently added to or reduced their stakes in SYRS. Vanguard Group Inc. boosted its stake in shares of Syros Pharmaceuticals by 21.3% in the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company's stock valued at $4,965,000 after buying an additional 163,234 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Syros Pharmaceuticals in the first quarter valued at approximately $64,000. Acadian Asset Management LLC boosted its stake in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company's stock valued at $178,000 after buying an additional 17,416 shares in the last quarter. Certuity LLC purchased a new stake in Syros Pharmaceuticals during the second quarter worth $109,000. Finally, GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals during the third quarter worth $34,000. Institutional investors and hedge funds own 91.47% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on SYRS shares. HC Wainwright reissued a "neutral" rating and issued a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reissued a "hold" rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reissued a "hold" rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com initiated coverage on Syros Pharmaceuticals in a research note on Friday, November 29th. They issued a "sell" rating for the company. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Syros Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $3.33.
Check Out Our Latest Stock Analysis on SYRS
About Syros Pharmaceuticals
(
Get Free Report)
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
